Danielle Patient Testimonial: WH Innovations Version

The Tipping Point: How clinically validated MRD testing is transforming patient management in colorectal cancer

Post ESMO review - How molecular residual disease testing is transforming cancer care

4379_Natera_Danielle_V4A - Captioned

ASCO24 Summary: Latest data on ctDNA as a patient selection and early efficacy marker in drug development

Latest data on ctDNA as a patient selection and early efficacy marker for gynecologic cancers

Natera Analogy of Radon Testing to Signatera testing - social - d1 - with captions

Natera Signatera gave me more time - social - d1 - with captions

Brent's Story

Using ctDNA to help inform the management of patients with low-risk colorectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with low-risk colorectal cancer

Using ctDNA to help inform the management of patients with locally advanced rectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with locally advanced rectal cancer

The expanding role of ctDNA in colorectal cancer to optimize patient management

The expanding role of ctDNA in colorectal cancer to optimize patient management (with subtitles)

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Review recently presented MRD data in colorectal and pancreatic cancer, exploring the potential impact on patient care

Seeing the Forest Through the Trees: Using tumor-informed MRD testing to illuminate the treatment pathway in GI cancer

Personalized ctDNA testing to help guide treatment decisions in breast cancer